Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen for X-linked Myotubular Myopathy
NCT04915846Phase 2Terminated
- Start
- Dec 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of tamoxifen in X-linked myotubular myopathy (XLMTM). Primary endpoint: Motor Function Measure 32 at 15 months. Started Dec 2020; status: terminated.
02
Drugs
tamoxifen
03
Conditions
X-linked myotubular myopathy (XLMTM)
Beyond the preview
Go deeper on NCT04915846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915846.